Fujian Shengdi Pharmaceutical Co., Ltd.
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS21
PHASE 3 / 2-38
RECRUITING11
READOUTS ≤12 MONTHS12
READOUT SLIPPED >6 MO0%
Delay Index: of 7 active trials registered more than a year ago, 0 have moved their primary completion (readout) date by more than 6 months since first registration (median +0.0 months). See all sponsors →
Open Fujian Shengdi Pharmaceutical Co., Ltd. on the live radar map →| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| HRS9531 NCT06391710 |
P2 | Active, not recruiting | Heart Failure With Preserved Ejection Fraction | 203 | 2026-01 (+4 mo) |
| HRS-5635 Injection NCT06425341 |
P2 | Recruiting | Chronic Hepatitis B | 369 | 2026-08-30 (+4 mo) |
| HRS-7249 Injection NCT07100418 |
P2 | Active, not recruiting | Hyperlipidemia | 224 | 2026-09 |
| HRS-9057 injection set NCT07318103 |
P2 | Recruiting | Fluid Retention Caused by Heart Failure | 153 | 2026-09 |
| HRS5580 for injection combined with palonosetron hydrochloride; NCT07709897 |
P2 | Recruiting | Prevention of Postoperative Nausea and Vomiting | 260 | 2026-12 |
| HRS-9563 Injection NCT07297797 |
P2 | Active, not recruiting | Mild to Moderate Hypertension | 238 | 2026-12 |
| HRS9531 NCT06994650 |
P3 | Active, not recruiting | Subjects With Moderate-to-severe OSA and Obesity Who Are on PAP Therapy | 144 | 2026-12 |
| HRS9531 NCT06974851 |
P3 | Recruiting | Bstructive Sleep Apnea (OSA) and Obesity | 140 | 2026-12 |
| HRS9531 NCT07060456 |
P3 | Recruiting | Type 2 Diabetes | 300 | 2027-02 |
| HRS-4729 Injection NCT07690826 |
P2 | Not yet recruiting | Overweight or Obesity | 252 | 2027-03 |
| HRS9531 injection NCT07285902 |
P3 | Active, not recruiting | Obesity | 572 | 2027-03 |
| HRS-5632 Injection NCT07185776 |
P2 | Active, not recruiting | Lipoprotein Disorder | 203 | 2027-04 |
| HRS-4729 Injection NCT07843862 |
P2 | Not yet recruiting | Type 2 Diabetes | 240 | 2027-04 |
| HRS9531 Tablet NCT07599410 |
P2 | Recruiting | T2DM | 240 | 2027-05 |
| HRS-7249 injection set NCT07308392 |
P2 | Active, not recruiting | Severe Hypertriglyceridemia With a High Risk of Acute Pancreatitis | 119 | 2027-06 |
| HRS9531 Tablet NCT07670884 |
P3 | Recruiting | Chronic Management of Body Weight | 675 | 2027-10-31 |
| HRS-4729 Injection NCT07660848 |
P2 | Recruiting | Metabolic Dysfunction-Associated Steatohepatitis (MASH) | 160 | 2028-03 |
| HRS-5635 Injection NCT07606950 |
P3 | Recruiting | Nucleos(t)Ide Analogue-suppressed HBeAg-negative Patients With Chronic Hepatitis B | 540 | 2028-06 |
| HRS-7249 Injection NCT07799688 |
P2 | Recruiting | Hyperlipidemia | 400 | 2028-10-15 |
| Ribupatide Injection NCT07709910 |
P3 | Not yet recruiting | Participants With Obesity and Knee Osteoarthritis | 382 | 2028-11 |
| HRS9531 NCT07551492 |
P3 | Recruiting | Atherosclerotic Cardiovascular Disease | 9262 | 2031-05-24 |